학술논문
Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer.
Document Type
Academic Journal
Author
Nunes-Xavier CE; Biomarkers in Cancer Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. Electronic address: carolinenunesxavier@gmail.com.; Emaldi M; Biomarkers in Cancer Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain. Electronic address: maite.emaldimartinezdeilarduya@osakidetza.eus.; Guldvik IJ; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. Electronic address: ingrid.jenny.guldvik@rr-research.no.; Ramberg H; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. Electronic address: hakon.ramberg@rr-research.no.; Taskén KA; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Norway. Electronic address: k.a.tasken@medisin.uio.no.; Mælandsmo GM; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; University of Tromsø - The Arctic University of Norway, Tromsø, Norway. Electronic address: g.m.malandsmo@ous-research.no.; Fodstad Ø; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. Electronic address: fodstadoystein@gmail.com.; Llarena R; Department of Urology, Cruces University Hospital, Barakaldo, Spain. Electronic address: roberto.llarenaibarguren@osakidetza.eus.; Pulido R; Biomarkers in Cancer Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, Spain. Electronic address: rpulidomurillo@gmail.com.; López JI; Biomarkers in Cancer Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain. Electronic address: jilpath@gmail.com.
Source
Publisher: Gustav Fischer Verlag Country of Publication: Germany NLM ID: 7806109 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-0631 (Electronic) Linking ISSN: 03440338 NLM ISO Abbreviation: Pathol Res Pract Subsets: MEDLINE
Subject
Language
English
Abstract
Prostate cancer diagnosis and early stratification is an important aspect to avoid undertreatment of high-risk prostate cancer patients. Major Vault Protein (MVP) has been proposed as a prognostic biomarker in prostate cancer. PTEN and the immune checkpoint protein B7-H3 interact with MVP and are important in prostate cancer progression and therapy response. We evaluated the expression of MVP by immunohistochemistry of tissue microarray samples from a retrospective cohort consisting of 119 prostate cancer patients. We correlated the protein expression of MVP with clinicopathological characteristics, and protein expression of androgen receptor (AR), PTEN, immune checkpoint proteins B7-H3 and PD-L1. We found MVP to be expressed in 53 % of prostate tumors, and correlated positively with biochemical recurrence (ρ = 0.211/p = 0.021). Furthermore, we found positive correlation of MVP expression with expression of AR (ρ = 0.244/p = 0.009) and the immune checkpoint protein B7-H3 (ρ = 0.200/p = 0.029), but not with PD-L1 (ρ = 0.152/p = 0.117) or PTEN expression (ρ = - 0.034/p = 0.721). Our findings support the notion that expression of MVP is associated with poor prognosis in prostate cancer. The correlation between MVP and immune checkpoint protein B7-H3 in prostate cancer suggests a role for MVP in immunoregulation and drug resistance.
(Copyright © 2022 The Authors. Published by Elsevier GmbH.. All rights reserved.)
(Copyright © 2022 The Authors. Published by Elsevier GmbH.. All rights reserved.)